| Literature DB >> 27793136 |
Øyvind Salvesen1, Malin R Reiten1, Peter M H Heegaard2, Michael A Tranulis1, Arild Espenes1, Kerstin Skovgaard2, Cecilie Ersdal3.
Abstract
BACKGROUND: Sepsis is a serious health problem associated with a range of infectious diseases in animals and humans. Early events of this syndrome can be mimicked by experimental administration of lipopolysaccharides (LPS). Compared with mice, small ruminants and humans are highly sensitive to LPS, making goats valuable in inflammatory models. We performed a longitudinal study in eight Norwegian dairy goats that received LPS (0.1 μg/kg, Escherichia coli O26:B6) intravenously. A control group of five goats received corresponding volumes of sterile saline. Clinical examinations were performed continuously, and blood samples were collected throughout the trial.Entities:
Keywords: Blood leukocyte gene expression; Endotoxemia; Extrahepatic acute phase proteins; Goat; Innate immunity; Interferon stimulated genes; Lipopolysaccharide (LPS); Systemic inflammation
Mesh:
Substances:
Year: 2016 PMID: 27793136 PMCID: PMC5084394 DOI: 10.1186/s12917-016-0870-x
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Fig. 1Rectal temperature and hematology after systemic LPS challenge. Rectal temperature (a), and blood leukocyte count including neutrophils (b), lymphocytes (c) and monocytes (d) following 0.1 μg/kg intravenous LPS administration. Values are mean ± SEM, n = 8
Fig. 2Acute phase protein (APP) genes and serum levels of SAA after systemic LPS challenge. a Relative mRNA expression of serum amyloid A3 (SAA3), haptoglobin (HP), lactoferrin (LF) and lipocalin 2 (LCN2), compared with baseline levels (0 h) scaled to 1. Real time qPCR was performed on RNA extracted from circulating leukocytes at the indicated time points. Results are shown as mean relative fold change ± SEM. b Circulating levels of serum amyloid A (SAA) shown as mean serum concentration (ng/ml) ± SEM. The y-axis dotted line indicates the lower detection limit of the ELISA (470 ng/ml). n = 8
Fold change in gene expression of selected immune genes after LPS challenge
| Gene | mRNA fold change |
| Gene | mRNA fold change |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 h | 2 h | 5 h | 24 h | 1 h | 2 h | 5 h | 24 h | ||||||
| Interferon stimulated genes | CXCL10 | 4 |
| 11 | 2 |
| LPS-pathway | TLR4 | −2 | 2 |
| 1 |
|
| ISG15 | 2 |
| 17 | 4 |
| CD14 |
| 1 | 1 | 1 |
| ||
| ISG20 | 1 |
| 7 | 3 |
| MyD88 |
| 1 | 1 | 1 |
| ||
| IFIT1 | 1 |
| 3 | 1 |
| TRAF6 | 1 | −2 | − | −2 |
| ||
| OAS1 | 1 |
| 7 | 2 |
| IFN-pathway | STAT1 | 1 |
| 2 | 1 |
| |
| IFI6 | 1 | 5 |
| 3 |
| Cytokines and chemokines | IL1B | 2 | 2 |
| 2 |
| |
| MX1 | 1 |
| 11 | 2 |
| IL8 | 2 |
| 2 | 1 |
| ||
| Acute phase proteins | SAA3 | 4 | 80 |
| 10 |
| CCL3 | 3 | 2 |
| 1 |
| |
| LF | 3 | 5 |
| 2 |
| CCL5 | −4 | −3 | −1 |
|
| ||
| HP | 8 | 14 |
| 1 |
| IL18 | −3 |
| −3 | 1 |
| ||
| LCN2 | 2 | 2 |
| −2 |
| IL1RN | 1 |
| 7 | 1 |
| ||
| Enzymes | HSPA1A | 1 | 3 |
| 1 |
| Other immune- related genes | TICAM | 1 | −3 |
| −2 |
|
| S100A9 | 1 | 8 |
| 3 |
| ITGB2 | −2 | −2 | − | 1 |
| ||
| SOD2 | −3 | 3 |
| 1 |
| MHCII | 1 | −2 |
| 1 |
| ||
Relative gene expression following intravenous LPS (0.1 μg/kg) administration in goats. Fluidigm qPCR was performed on RNA extracted from circulating leukocytes at the indicated time points. Results are expressed as mean fold change relative to baseline samples (0 h) scaled to 1. The most regulated time point for each gene is highlighted in bold, and significance level at this time point is given
Fig. 3Gene expression of leukocyte ISGs (a-f), IFNB1 (g) and STAT1 (h) after systemic LPS challenge. Relative mRNA fold change compared with baseline levels (0 h) scaled to 1. Real time qPCR was performed on RNA extracted from circulating leukocytes at the indicated time points. Results are expressed as mean relative fold change ± SEM, n = 8. NS = not significant. *P < 0.05; **P < 0.01; ***P < 0.001